alexa Novel Immunotherapy to Eliminate Minimal Residual Disease in AML Patients

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Novel Immunotherapy to Eliminate Minimal Residual Disease in AML Patients

Standard chemotherapy for adults with AML (Acute Myeloid leukemia) can induce remission but is not curative for the majority of patients who will eventually relapse and die of their disease. Immunotherapy represents a potentially efficacious adjunct to standard AML therapy, particularly for those in the Minimal Residual Disease (MRD) state during which immune-based therapies may be most effective. Unfortunately, the efficacy of cancer immunotherapy has been limited by a number of immune evasion pathways which suppress anti-tumor immunity and enable tumor progression. A major focus of our research group has been to characterize immune evasion pathways promoted by AML with the ultimate goal of blocking such pathways to unleash the full effectiveness of immunotherapy for leukemia.

 

 

 

Citation: Liu H, Kline J (2013) Novel Immunotherapy to Eliminate Minimal Residual Disease in AML Patients. J Hematol Thromb Dis 1:112. doi:10.4172/2329-8790.1000112

 
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
 
adwords